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resumo 
 
 
Um dos principais mecanismos reguladores da função celular é a fosforilação 
de proteínas. É de focar que a fosforilação anormal de proteínas-chave pode estar 
associada a várias patologias, incluindo o cancro. Embora já existam muitos estudos 
sobre cinases no cancro, o conhecimento sobre as fosfatases que antagonizam a acção 
das cinases é muito menos.  
A PP1, uma das principais proteínas fosfatase de serina/treonina expressa em 
todas as células eucarióticas, está envolvida em vários processos celulares incluindo 
apoptosis e ciclo celular. Na realidade, diversos estudos demonstram que a PP1 regula 
variadas proteínas que são elementos-chave no processo de tumorigenesis. A AKT, 
uma cinase serina/treonina que se encontra desregulada em vários tipos de cancro, é um 
factor crucial na progressão e sobrevivência de melanoma. 
Prodigiosina, um membro da família de metabolitos secundários tripirrolicos 
pigmentados de vermelho, as prodigininas, demonstra propriedades anticancerigenas 
em vários tipos de cancro. Na verdade alguns estudos verificaram que a AKT é 
desfosforilada pela prodigiosina embora ainda seja desconhecido o mecanismo pelo 
qual tal acontece. Dada a importância da AKT na progressão e sobrevivência do 
melanoma e a capacidade da PP1 em desfosforilar a AKT é possível que a PP1 esteja 
envolvida em tal mecanismo. 
Os resultados preliminares demonstraram que a PP1 liga-se a um membro da 
família das prodigininas provando a interacção entre estas moléculas. Por outro lado, 
ensaios em linhas celulares de melanoma usando tratamentos com prodigiosina e 
cantaridina, um inibidor da PP1, demonstraram que a prodigiosina afecta isoformas da 
PP1 diferencialmente. Estes resultados sugerem que a prodigiosina actua em duas vias 
de sinalização distintas em melanoma, a via da AKT e a da MAPK, uma vez que 
alteração nos níveis de PP1α, uma das isoformas da PP1, se correlaciona com a 
variação dos níveis de fosforilação da AKT e as mudanças nos níveis da PP1γ com a 
variação dos níveis de fosforilação da MAPK.  
Com estes resultados propomos um modelo de como a prodigiosina 
desfosforila a AKT e como este processo contribui para a indução da morte celular em 
células de melanoma. Esperamos que este modelo ajude na compreensão do mecanismo 
de acção da prodigiosina bem como no reconhecimento das fosfatases como novos 
alvos terapêuticos no tratamento de cancro.  
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abstract 
 
Protein phosphorylation is a major regulatory mechanism for cell function. It 
is noteworthy that several pathologies, including cancer to be associated with abnormal 
phosphorylation of key proteins. Although many studies have addressed the kinases 
that are misregulated in cancer, much less is known about the phosphatases that 
counteract their actions. 
PP1, a major serine/threonine protein phosphatase that is ubiquitously 
expressed in all eukaryotic cells, is involved in many cellular processes including 
apoptosis and cell cycle. In fact, several studies demonstrate that PP1 regulates several 
proteins that are key elements in the tumorogenesis process. AKT, a serine/threonine 
kinase that is disregulated in several types of cancer is a crucial factor in melanoma 
progression and survival.  
Prodigiosin, a family member of the natural red pigmented tripyrrolic 
secondary metabolites, prodiginines, show anticancer properties in numerous types of 
cancer. In fact, some prodigiosin studies demonstrate that AKT is dephosphorylated by 
prodigiosin by an unknown mechanism. Given the importance of AKT in melanoma 
progression and survival and the capacity of PP1 to dephosphorylate AKT it is possible 
that PP1 is involved in this mechanism. 
Our preliminary results showed that PP1 binds to one member of prodiginine 
family proving the interaction between these molecules. On the other hand, experiments 
with melanoma cell lines, using prodigiosin and cantharidin, a PP1 inhibitor, 
treatments, demonstrate that prodigiosin affect differently PP1 isoforms. These results 
suggest that prodigiosin acts in a different way in two altered pathways in melanoma, 
AKT and MAPK, since the alterations in PP1α levels, one of PP1 isoforms, are 
correlated with the conversion in AKT dephosphorylation and the variations in PP1γ 
levels with the changes in MAPK dephosphorylation. 
Given these results we propose a model of how prodigiosin dephosphorylates 
AKT and how this process contributes to induce cell death in melanoma cells. We 
expect that this model helps to understand prodigiosin action mechanism as well as 
acknowledge phosphatases as a therapy target in cancer treatment. 
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Abbreviations 
4E-BP1     Inhibition of the elongation–initiation factor E4 binding protein 
ADP    Adenosine diphosphate 
AIF      Apoptosis-inducing factor 
AKT/PKB     v-akt murine thymoma viral oncogene homolog/protein kinase B 
APAF     Apoptotic protease-Activating Factor 1 
APS      Amonium Persulfate 
ATM      Ataxia telangiectasia mutated gene product 
ATP      Adenosine triphosphate 
BAD    Bcl-2-associated agonist of cell death 
BAX    Bcl-2-associated X protein 
BCA      Bicinchoninic acid  
Bcl-2    B-cell CLL/lymphoma 2 
Bcl-XL    Bcl-2-like 1 
Bcl-W    Bcl-2-like 2 
Bik    Bcl-2-interacting killer 
Bim    Bcl-2-like 11 
BRAC 1     Breast cancer 1 
BSA      Bovine serum albumin 
CANT    cantharidin 
Cdk      Cyclin-dependent kinase 
c-Myb    v-myb myeloblastosis viral oncogene homolog 
CREB    cAMP responsive element binding protein 1 
DSP      Dual-Specificity Phosphatase 
DNK-PK     DNA-dependent protein kinase 
E2F    E2F transcription factor  
ECL      Enhanced chemiluminescence 
eNOS    nitric oxide synthase 3 
ERK    mitogen-activated protein kinase 
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Fas-L    Fas ligand 
FBS      Foetal bovine serum 
FCP/SCP   TFIIF-associating component of RNA polymerase II CTD 
phosphatase/small CTD phosphatase 
GLUT4    solute carrier family 2, member 4 
GSK3      Glicogen synthase kinase-3 
hTERT    human telomerase reverse transcriptase   
IGFBP-1   insulin-like growth factor binding protein 1 
IKK      Ikappa B kinase 
ILK      Integrin-linked kinase 
MAPK     Mitogen-activated protein kinase 
Mcl-1    myeloid cell leukemia sequence 1 
Mdm2     Murine double minute-2 protein 
MEK    mitogen-activated protein kinase kinase 
MEM      Minimum Essential Medium 
Min      Minute 
MMP      Matrix metalloproteinase 
mTOR      Mammalian target of rapamycin 
NEAA      Non-essential amino acids  
NEK6    NIMA-related kinase-6 
NF-KB     Nuclear factor-kB 
OBX    Obatoclax 
PDK 1      Phosphoinositide-dependent kinase-1 
PDK 2      Phosphoinositide-dependent kinase-2 
PPs    Protein Phosphatases 
PG    Prodigiosin 
PH      Pleckstrin homology 
PHLPPs     PH-domain phosphatases  
PI3K     Phosphoinositide-3-kinase 
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PIP    Phosphatase Interacting Protein  
PIP2     Phosphatidylinositol-4,5-biphosphate 
PIP3     Phosphatidylinositol-3,4,5-triphosphate 
PKC     Protein kinase C 
PP      Protein Phosphatase 
PP1     Protein phosphatase 1 
PP1c     Protein phosphatase 1 catalytic subunit 
PP2A     Protein phosphatase 2A 
PP2B     Protein phosphatase 2B 
PP2C     Protein phosphatase 2C  
PPM     Metal-dependent protein phosphatase  
PPP     Phosphoprotein phosphatase 
PTEN     Phosphatase and tensin homologue deleted on chromosome 10 
PTP     Protein tyrosine phosphatase 
RAF    v-raf murine sarcoma viral oncogene homolog 
RAS    rat sarcoma viral oncogene homolog 
RU      Resonance Units 
S6K1     Ribosomal S6 kinase 
SDS     Sodium dodecyl sulphate 
SDS-PAGE     Sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
Ser      Serine  
SHIP     SH2 domain-containing inositol 5- phosphatase 
SPR     Surface Plasmon Resonance 
STPP    Serine/Threonine Specific Protein Phosphatases 
TBST     TBS supplemented with Tween detergent 
TEMED     N, N, N´, N' – Tetramethylethylenediamine 
Thr      Threonine 
TSC1     Tuberous sclerosis complex 1 
TSC2     Tuberous sclerosis complex 2 
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1.1 Protein (de)phosphorylation in cancer 
 
1.1.1 Protein Phosphorylation  
 Protein phosphorylation is central to the regulation and control of proteins and 
cellular functions. This process is catalysed by kinases and reversed by protein 
phosphatases (PPs) forming a dynamic system that controls several signal transduction 
cascades. This system involves three main components: a kinase, responsible for the 
addition of one phosphate group via transference of the terminal phosphate from ATP to an 
amino acid residue; a phosphatase, responsible for the hydrolyses of the phosphate group; 
and a target protein or phosphoprotein whose properties change according to its 
phosphorylation state (figure 1) (Cruz e Silva 1998).  
 
 
Figure 1: Schematic representation of reversible protein phosphorylation. Protein Phosphatase removes a phosphate 
group from the phosphoprotein and the protein kinase transfers the phosphate group from ATP to the phosphoprotein. 
 
Phosphorylation/dephosphorylation reactions can affect activity, function, half-life, 
or subcellular localization of the phosphoproteins (McConnell and Wadzinski 2009). 
The importance of phosphorylation networks in eukaryotes is underscored by the 
estimated one-third of cellular proteins that are phosphorylated with the vast majority of 
the modifications occurring on tyrosine, serine and threonine (Virshup and Shenolikar 
2009).  
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   Sequencing of entire genomes has revealed that nearly 3% of all eukaryotic genes 
encode kinases or protein phosphatases (Cohen 2002). The human genome encodes just 
about 500 protein kinases, of which approximately two thirds are serine/threonine kinases. 
However, the four distinct families of protein phosphatases comprise only near 150 
members, of which fewer than 40 are serine/threonine phosphatases (Cohen 2002). A 
single phosphatase catalytic moity often associates with several different regulatory or 
targeting subunits, allowing the total number of functional phosphatase holoenzymes to be 
similar to the number of protein kinases (Klumpp and Krieglstein 2002). 
 Knowing the scale of this process, it is not surprising that cellular health and 
vitality are dependent on the fine equilibrium of protein phosphorylation systems as well 
as, abnormal phosphorylation of key proteins can lead to several diseases like 
neurodegenerative conditions, diabetes, cardiac hypertrophy and cancer (Fardilha, Esteves 
et al. 2010). 
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1.1.2 Protein Phosphatase 1 (PP1)  
PPs can be classified according to substrate specificity and are usually divided into 
two major groups, the protein tyrosine phosphatases (PTPs) and the serine/threonine 
specific protein phosphatases (STPPs) (figure 2) (Ingebritsen and Cohen 1983).  
The PTP family is a heterogeneous group of enzymes that can be separated into the 
classical PTPs and the dual-specificity phosphatases (DSP) (figure 2). Classical PTP can 
still be divided in non-transmembrane protein tyrosine phosphatases, which share similar 
PTP domains but have additional elements that establish both their location and function 
within the cell, and receptor-type protein tyrosine phosphatase, which have a 
transmembranar domain that retains them within the plasma membrane (figure 2) (Cohen 
1989; Berridge 2009).  
PTPs catalyze dephosphorylation reactions on phospho-tyrosine residues, STPPs on 
phospho-serine and phospho-threonine residues, and DSP, as the name implies, can 
dephosphorylate both phospho-tyrosine and phospho-serine/phospho-threonine residues 
(Berridge 2009; McConnell and Wadzinski 2009). STPPs and PTPs have distinct catalytic 
and regulatory mechanism. PTPs use a catalytic cysteine residue as a nucleophile, whereas 
the STPP nucleophilic attack is facilitated via a metal-activated water molecule positioned 
in the catalytic groove (McConnell and Wadzinski 2009). 
STPPs were initially divided into two classes bared on their biochemical properties: 
the type-1 and type-2 PPs. The type-1 PPs were susceptible to heat-stable proteins, 
inhibitor-1(I-1) and inhibitor-2 (I-2) and preferentially dephosphorylated the β-subunit of 
phosphorylase kinase, while type-2 PPs were insensitive to the heat-stable inhibitors and 
preferentially dephosphorylate α-subunit of phosphorylase kinase. Type-2 PPs were further 
subdivided according to the effect of divalent cations into three classes: cation independent 
(PP2A), Ca
2+
 dependent (PP2B) and Mg
2+
 dependent (PP2C) (Ingebritsen and Cohen 
1983; Cohen 1989). 
Currently, STPPs are classified based in their amino acid sequence homology 
(figure 2). Three distinct STPP gene families have been described: PPM (metal-dependent 
protein phosphatase), the aspartate-based phosphatases represented by FCP/SCP (TFIIF-
associating component of RNA polymerase II CTD phosphatase/small CTD phosphatase) 
and PPP (phosphoprotein phosphatases) (Shi 2009; Fardilha, Esteves et al. 2010). PPM 
family comprises the Mg
2+
/Mn
2+
 dependent PPs, such as pyruvate dehydrogenase, PP2C 
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and relatives (Barford, Das et al. 1998). The FCP family includes the new FCP1 and SCPs 
1-3 which share a common substrate – terminal domain of RNA polymerase II (McConnell 
and Wadzinski 2009). The PPP family consists on the protein phosphatase 1 (PP1), PP2A, 
PP2B, subfamilies that share high homology in the catalytic domains and probably share 
similar catalytic mechanism but differ in the N- and C-terminus (Cohen 1997; Barford, Das 
et al. 1998). Related novel protein phosphatases, such as PP4, PP5, PP6 and PP7 were 
characterized recently and have a tissue and development-specific manner and a lower 
abundance (Cohen 1997; Wang, Zhang et al. 2008). 
The use of some drugs, like okadaic acid and cantharidin, also helps to differentiate 
between families and even between members of the same family according to the 
concentration of the drug (e.g. PP2C is not sensitive to cantharidin or okadaic acid but PP1 
and PP2A are; however PP2A is more sensitive to cantharidin than PP1; PP1 IC50 
cantharidin – 450nM; PP2 IC50 cantharidin – 50nM) (Cruz e Silva 1998). 
Members of PPP family form multimeric holoenzyme complexes with a wide 
variety of regulatory, scaffolding, targeting, and inhibitory proteins. These binding proteins 
assign substrate selectivity and direct subcellular localization to the catalytic subunit 
making distinct phosphatase holoenzymes, composed by a catalytic subunit and an 
associated regulatory subunit(s), highly regulated and specific (Janssens and Goris 2001). 
Besides, post-translational modifications of phosphatase catalytic and regulatory subunits 
afford additional regulation for some PPP family members. 
 
Figure 2: Schematic representation of the major protein phosphatases families and their respective main members. 
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PP1 is a major STPP and is ubiquitously expressed in all eukaryotic cells being 
important in a wide range of cellular processes, including meiosis and cell division, 
apoptosis, cytoskeletal reorganization, protein synthesis and the regulation of membrane 
receptors and channels. (Cohen 2002; Ceulemans and Bollen 2004) 
Three genes encode PP1c isoforms in mammalians: PP1α, PP1β (also termed PP1δ) 
and PP1γ with distinct tissue distribution and subcellular localization (da Cruz e Silva 
1995). PP1α and PP1γ can arise through alternative splicing forming two isoforms of 
PP1α, PP1α1 and PPα2, and two isoforms of PP1γ, PP1γ1 and PP1γ2 (Cohen 2002). 
 PP1 is a heterodimer composed by a catalytic subunit (PP1c) and a regulatory 
subunit (R subunit). The small number of PP1c isoforms, their high homology and their 
broad and similar substrate specificities in vitro suggest that it is predominantly the 
regulatory subunits with which PP1c interacts, that control the specificity and diversity of 
PP1 function. 
 The regulatory subunits can be divided, based on their main effect on PP1c, into 
three groups: activity-modulating proteins, targeting proteins and substrates (Bollen 2001). 
The activity-modulating proteins, as the name indicates, are represented by proteins that 
modulate the activity of PP1c such as inhibitors (i.e. inhibitor-1). The group of targeting 
proteins are composed by proteins that bind to PP1c and one of its substrate or associate 
with a subcellular structure that contains the substrate. This group also includes the 
scaffolding proteins which mediate the formation of protein complexes. The last group 
includes substrates that directly and tightly associate with PP1c, though some substrates act 
also as a targeting protein or an activity-modulating protein (Bollen 2001). 
Most of the members of these groups have been shown to bind PP1c via a short 
sequence that is referred to as the RVxF motif (Ceulemans and Bollen 2004). Although the 
sequences that correspond to the RVxF motif are degenerate (the consensus sequence is 
[K/R]-X0-1-[V/I]-(P)-[F/W], the evidence for their role in the binding to PP1c is convincing 
for various reasons. First, the co-crystallization of PP1c with a synthetic fragment of the 
muscle-type G subunit showed that the RVxF sequence binds tightly in an extended 
conformation to a hydrophobic channel of PP1c that is remote from the catalytic site. 
Furthermore, it has been demonstrated that mutation of the hydrophobic (V/I) and/or 
aromatic (F/W) residue in this motif disrupts or weaken their interaction with PP1c. 
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Additionally, synthetic peptides containing RVxF motif can competitively disrupt or 
weaken the binding of various R subunits to PP1c (Bollen 2001). 
Binding to the RVxF sequence does not cause significant conformational changes 
in the catalytic subunit however increases the local concentration of R subunits, promoting 
secondary interactions that can affect the activity and specificity of PP1c (Hendrickx, 
Beullens et al. 2009). In the same way, the disruption of a single phosphatase-binding 
motif, like RVxF, could weaken or disrupt the interaction of the R subunit and PP1c which 
might affect the activity and substrate specificity of the holoenzyme, although the binding 
of the RVxF sequence itself has no major effect on PP1c. The final outcome of a disruption 
of the RVxF motif will depend on the number, affinity and interdependency of the 
remaining phosphatase-binding sites. These evidences suggest that the binding of the R 
subunit to PP1c is mediated by multiple, degenerate, short sequences motifs and that the R 
subunits can share interactions sites (Bollen 2001). This means that distinct effects of the R 
subunits on PP1c could simply be accounted for by their association with different subsets 
of a limited number of binding sites working as a combinatorial-control (figure 3).    
  
 
Figure 3: Combinatorial-control model of the catalytic subunit of protein phosphatase 1 (PP1c). The R subunits can be 
activity-modulators (R1), targeting proteins (R2) and/or substrates (R3). It is thought that the R subunits have several 
contacts with PP1c and that they can share binding sites.  The specificity is achieved by association with different subsets 
of binding sites on PP1c (adapted from Bollen, 2001). 
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1.1.3 PP1 in cancer  
 PP1 regulates diverse proteins in the cell; some of them tightly related with 
apoptosis and/or cell cycle arrest so it is not surprising that PP1 can be involved in 
tumorogenesis. 
 One of these proteins are the Bcl-2 family proteins (Ayllon, Cayla et al. 2001; 
Garcia, Cayla et al. 2003). The Bcl-2 family proteins play an important role in induction 
through BAD, BAX, Bik and suppression through Bcl-2, Bcl-XL of apoptosis. These 
proteins are regulated by at least three different ways. The first results in an altered 
expression rate; the second is through proteolytic cleavage by caspases and the third is as a 
result of reversible post-translational modifications via phosphorylation/ 
dephosphorylation. This last mechanism is the main mechanism that directly regulate the 
functional activity of both antiapoptotic and proapoptotic proteins of the Bcl-2 family 
(Klumpp and Krieglstein 2002). 
 BAD is a proapoptotic protein that interacts with Bcl-2 and with Bcl-XL (anti-
apoptotic proteins). BAD modulates the function of these proteins by direct interaction 
through BH3 domains; however the formation of this heterodimer is determined by the 
phosphorylation status of BAD. PP1α dephosphorylates BAD on Ser-112 and Ser-136 
prior to induction of apoptosis in response to IL-2 deprivation (Ayllon, Cayla et al. 2001). 
Still, it seems that it is Bcl-2, through the PP1 binding motif, RIVAF that binds and target 
PP1α to BAD forming a trimolecular complex (Garcia, Cayla et al. 2003). In addition a 
second motif was characterize, F-x-x-[RK]-x-[RK], present in the BH3 domain, while the 
RVxF motif is present in the BH1 domain (Garcia, Cayla et al. 2003).  
The relationship between PP1 and pRb, the tumor suppressor product of the 
retinoblastoma susceptibility gene, is also well known (Weinberg 1995; Tamrakar, Rubin 
et al. 2000; Vietri, Bianchi et al. 2006). pRb is a key regulator of the cell cycle controlling 
G1-S-phase transition by interacting with several cellular proteins depending on its 
phosphorylation state. During early G1, pRb is hypophosphorylated functioning as a 
growth suppressor. Hypophosphorylated pRb forms complexes with E2F family 
transcription factors, sequestering it and preventing the transcription of genes required to 
enter in S-phase (Tamrakar, Rubin et al. 2000). In middle to late G1, Cdks phosphorylate 
pRb resulting in the release and activation of E2F and other pRb-bound transcription 
factors, which activate the transcription of S-phase genes (Ludlow and Nelson 1995). In 
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the M-G1 transition pRb is progressively dephosphorylated by PP1, returning to its 
growth-suppressive hypophosphorylated state (Vietri, Bianchi et al. 2006). Due to its 
important role in the regulation of cell cycle, the inactivation of pRb by 
hyperphosphorylation or mutation is a common hallmark (Chatterjee, George et al. 2004). 
In an opposite way PP1 having the ability to activate this tumor suppressor could function 
in cancer prevention. 
The interaction between PP1 and BRAC1 was also reported (Winter, Bosnoyan-
Collins et al. 2007). The breast cancer susceptibility gene, BRAC1 is related to the 
development of a significant proportion of familial breast and ovarian cancer and sporadic 
breast cancer (Fraser, Reeves et al. 2002). It seems that phosphorylation of BRAC1 may 
have an important function throughout the cell cycle because it is hypophosphorylated 
during G1/S phase but becomes phosphorylated from S to G2/M phase. Additionally 
BRAC1 interacts with kinases involved in cell cycle control and apoptosis, like the 
cyclin/cdk complexes (Chen, Farmer et al. 1996). Some studies provided evidence for an 
important role of PP1 in the development of breast cancer, possibly through its association 
with BRCA1 suggesting that deregulation of the phosphorylation/dephosphorylation 
processes may be crucial to breast tumorigenesis (Winter, Bosnoyan-Collins et al. 2007). 
 The tumor suppressor p53, a master regulator of apoptosis in several types of cells, 
is also regulated by PP1 (Li, Liu et al. 2006). The loss of function of this protein has been 
reported as sufficient to inactivate the apoptotic machinery in many types of cancer cells as 
well as noncancer cells (Shen and White 2001). The regulation of apoptosis by p53 is made 
by two major mechanisms: p53 can act as a transcriptional factor controlling the 
expression of several genes involved in apoptosis and can activate BAX in mitochondria 
which will antagonize the antiapoptotic function of Bcl-2 and Bcl-XL(Shen and White 
2001). The transcriptional activity of p53 is regulated through post-translational 
mechanisms including phosphorylation/ dephosphorylation (Giaccia and Kastan 1998).  It 
has been shown that PP1 promotes survival through dephosphorylation of p53 at the 
residues Ser-15 and Ser-37. This dephosphorylation negatively regulates the transcriptional 
and apoptotic abilities of p53 (Li, Liu et al. 2006). 
Recently it was discovered in apoptosis-inducing factor (AIF) and apoptotic 
protease-Activating Factor1 (APAF-1), two major and distinct effectors of apoptosis, a 
sequence containing 10 amino acid residues that combine the two consensus motifs 
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identified in certain Bcl-2 proteins (R/Kx(0,1)V/IxFxx(R/K)x(R/K)) (Godet, Guergnon et 
al. 2010). These results suggest that the combinatorial PP1c docking motif 
R/Kx(0,1)V/IxFxx(R/K)x(R/K) is a new PP1c-dependent Apoptotic signature (Godet, 
Guergnon et al. 2010). 
 Since phosphorylation/dephosphorylation is important in the regulation of several 
mechanisms, including tumorogenesis, it is not surprisingly that PP1 is capable of regulate 
many proteins involved in cancer onset and progression. Nevertheless, although many 
studies exist on kinases regulation cancer signaling pathways, much less is known about 
phosphatases, particularly about PP1 and its interacting proteins. 
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1.2 AKT related pathways in melanoma 
 
1.2.1 PP1/AKT complex  
 AKT/PKB (v-akt murine thymoma viral oncogene homolog/protein kinase B) is a 
Ser/Thr kinase which belongs to the AGC (AMP/GMP kinases and protein kinase C) 
family of kinases. Mammalian cells express three closely related AKT isoforms: AKT1 
(PKBα), AKT2 (PKBβ) and AKT3 (PKBγ). AKT1 is ubiquitously expressed at high levels, 
while AKT2 is increased in insulin-sensitive tissues like liver, skeletal muscle and adipose 
tissue and AKT3 is highly expressed in the brain and testis (Franke 2008).     
The three AKT isoforms (AKT1, AKT2, AKT3) share similar structures, namely an 
N-terminal regulatory domain including a pleckstrin homology (PH) domain, a central 
catalytic domain and a C-terminal region regulatory hydrophobic motif (HM) (Nicholson 
and Anderson 2002; Franke 2008) (figure 4). Although structural homology between the 
different AKT isoforms, several findings point to functional differences between them. For 
instance, the glucose uptake in wild-type adipocytes is potently inhibited by siRNA 
knockdown of AKT2 but not AKT1 (Jiang, Zhou et al. 2003).  
 
 
Figure 4: Domain structure of the three human PKB/Akt isoforms. Each isoform consists of an N-terminal PH domain, a 
kinase domain and a C-terminal regulatory. The residues presented are serine and threonine sites 
phosphorylated/dephosphorylated to activate/deactivated AKT. The PP1 binding motif is also represented (triangle). 
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 Among the three members only the activation of AKT1 is well studied. AKT is 
activated through a series of phosphorylation events (figure 5). Until recently it was 
believed that AKT need to be phosphorylated at threonine residue-308 in its kinase domain 
and at serine residue-473 within the hydrophobic motif in the C-terminal to become fully 
activated. However a recent study has shown that AKT1 is first primed through 
phosphorylation at Thr-450 in the cytosol by the stress-activated protein kinase, JNK1/2, 
under certain conditions (Shaw and Kirshenbaum 2006). Then, phosphoinositide-
dependent kinase-1 (PDK1) phosphorylates AKT1 at Thr-308, when both are recruited to 
the membrane by phosphatidylinositol-3,4,5-triphosphate (PIP3), causing a conformation 
change that expose the C-terminal hydrophobic motif. Finally, to AKT become fully 
activated the Ser-473 residue needs to suffer auto-phosphorylation or to be phosphorylated 
or by a second kinase referred as phosphoinositide-dependent kinase-2 PDK2 (Franke 
2008).        
 The inactivation of AKT signaling occurs at two levels. First, phosphatase and 
tensin homologue deleted on chromosome 10 (PTEN) dephosphorylates PIP3 preventing 
further activation of AKT. Second, PH-domain phosphatases (PHLPPs) dephosphorylate 
AKT1 at Ser-473, and then PP2A mediates the dephosphorylation of AKT1 at Thr-308. To 
AKT1 become fully inactivated, is necessary to be further dephosphorylated at Thr-450. A 
recent study demonstrates that overexpression of PP1α/β results in hypophosphorylation of 
AKT1 at Thr-450 and its knockdown causes the hyperphosphorylation of AKT in the same 
residue allowing to conclude that PP1 is a major phosphatase that dephosphorylates AKT1 
at Thr-450 (Xiao, Gong et al. 2010). This dephosphorylation significantly modulates AKT 
function concerning regulation of gene expression and negatively affects the 
phosphorylation of AKT1 at Thr-308 and Ser-473 which gives to PP1 an important role in 
the regulation of survival-promotion activity mediated by AKT. (Xiao, Gong et al. 2010). 
 Furthermore, other recent study demonstrates that sphingosine induces PP1-
dependent AKT dephosphorylation at Ser-473 in Jurkat cells (Thayyullathil, Chathoth et 
al. 2011). This discovery emphatizes the importance of PP1 in the regulation of AKT since 
PP1 has been related to the dephosphorylation of two important residues that regulate AKT 
activity.  
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Figure 5: Schematic representation of AKT-1 phosphorylation/dephosphorylation mechanism (adapted from Xiao, Gong 
et al. 2010).   
Although only the interaction between AKT1-PP1 is describe in the literature it is 
expected that PP1 also forms a complex and regulates the other isoforms of AKT (AKT2 
and AKT3) given the similarity and the presence of an RVxF motif in all isoforms (figure 
6).    
 
Figure 6: Analysis of homology of AKT isoforms using Blastp multiple sequence alignment. An analysis in Scan Prosite 
using several PP1 binding motifs shows a RAVDW motif (blue square) in common in all AKT isoforms.  
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1.2.2 PI3K/AKT pathway in melanoma 
Melanoma is the third major form of skin cancer accounting for only 3% of all skin 
cancers. However it carries the highest risk of mortality representing 65% of all skin 
cancer deaths (Stahl, Sharma et al. 2004; Cummins, Cummins et al. 2006).This type of 
skin cancer is the most prevalent form in sun-rich regions populated by caucasians, like 
Australia, southern Europe, South Africa and the southern United States (Ibrahim and 
Haluska 2009).Melanoma originates from pigment producing melanocytes in the skin. 
Melanocytes arise from neural crest-derived progenitor cells that migrate into the skin from 
the central nervous system. These cells are distributed at the junction of the epidermal and 
dermal layers of the skin. Melanomas can also arise from noncutaneous melanocytes found 
in the lining of the chrodial layer of the eye, the meninges, and the gastrointestinal and 
genitourinary tracts however this is more uncommon (Ibrahim and Haluska 2009). 
 The risk factors related to develop melanoma are multiple benign or atypical nevi, 
giant melanocytic nevus, familial history, personal history of melanoma or nonmelanoma 
skin cancer, UV light exposure, immunosuppression, photosensitivity, and light skin and 
blond hair (Cummins, Cummins et al. 2006).    
Early melanomas are curable with surgical excision but due the extraordinary 
metastatic ability and resistance to chemo-, immune- and radiotherapy, advanced stages of 
melanoma have a poor prognosis reducing the survival of only 6 to 10 months (Stahl, 
Sharma et al. 2004; Dai, Martinka et al. 2005; Ibrahim and Haluska 2009). 
The lack of effective therapeutic regimes demonstrates the imperative need to 
understand the major pathways and genes altered during melanoma development in order 
to discover potential therapeutic molecular targets. These investigations led the 
identification of phosphoinositide-3-kinase (PI3K)/AKT pathway, among others as RAS-
RAF-MEK-ERK pathway or WNT pathway involved in melanoma (Lopez-Bergami, 
Fitchman et al. 2008). 
Several studies have reported increased levels of phosphorylated AKT (AKTp) in 
melanoma (Dhawan, Singh et al. 2002; Stahl, Sharma et al. 2004). High levels of AKTp 
were found in severely dysplastic nevi and metastatic melanomas compare to normal or 
mildly dysplastic nevi (Dhawan, Singh et al. 2002). Recently it was shown that the 
predominant isoform responsible for elevated AKTp levels in melanomas is AKT3 and 
comparing series of metastic melanomas with normal melanocytes reveal that deregulated 
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AKT3 expression or activity occurred in 43-67% of cases (Stahl, Sharma et al. 2004; 
Robertson 2005).   
The PI3K/AKT signaling is a key regulatory pathway of survival of cancer cells 
and has been shown to be constitutively active in melanoma and others cancers (figure 7) 
(Smalley and Herlyn 2005). Its activation occurs through growth factor receptors activation 
or loss of negative regulators of the pathway and the activation of AKT is PI3K-dependent 
(Hanada, Feng et al. 2004).  
PI3K is a lipid kinase with the ability to phosphorylate inositol ring 3’-OH group in 
inositol phospholipids. The class-I PI3Ks are heterodimers composed by a catalytic subunit 
(p110) and an adaptor/regulatory subunit (p85) (Vara, Casado et al. 2004). This class can 
be subdivided into the class-IA which is activated by receptors with protein tyrosine kinase 
activity and class-IB which is primarily regulated by small G-proteins such as Ras and by 
the β/γ subunits of G protein-coupled receptors (Vara, Casado et al. 2004; Franke 2008). 
PI3K is recruited to the membrane through specific phospho-tyrosine residues on 
the activated receptor or on associated adaptor proteins which binds the SH2 domain of the 
p85 subunit. The p110 domain can also be recruited and activated through the activity of 
the small GTPases Ras (Smalley and Herlyn 2005). 
 Active PI3K then phosphorylates phosphatidylinositol-4,5-biphosphate (PIP2) on 
the 3-OH group generating the second messenger PIP3. The levels of PIP3 are regulated by 
PTEN which dephosphorylates at the 3-OH position and SH2 domain-containing inositol 
5- phosphatase (SHIP) which removes phosphate from the 5-OH position (Nicholson and 
Anderson 2002).PIP3 recruits a subset of signaling proteins with pleckstrin homology (PH) 
domain to the membrane, including AKT. There, altered conformation of AKT mediated 
by PIP3 binding, expose the main phosphorylation sites allowing subsequent 
phosphorylation by Phosphoinositide-dependent kinase-1 (PDK-1). 
PDK-1 is a serine/threonine kinase containing a C-terminal PH domain that binds 
with high affinity to PIP3, so it is likewise that the PH domains may mediate the AKT and 
PDK-1 approach through their heterodimerization (Nicholson and Anderson 2002; Vara, 
Casado et al. 2004). PDK-1, which is thought to be constituently active, phosphorylates 
AKT in the activation loop (T305), which regulates access to the catalytic site of AKT. 
    Although phosphorylation at T305 partially activates AKT, full activation 
requires phosphorylation on a second site (S472) located in the hydrophobic C-terminal 
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region. The mechanism mediating S472 remains controversial. Modification of S472 has 
been shown to occur through autophosphorylation (Toker and Newton 2000) but other 
findings propose that S472 phosphorylation can be mediated by other serine kinases 
(PDK2). Several studies suggest a role for protein kinase integrin-linked kinase (ILK) in 
the activation process but a subsequent report shows that ILK acts only as a facilitator and 
does not phosphorylate AKT directly (Delcommenne, Tan et al. 1998; Lynch, Ellis et al. 
1999). There are other studies that suggest PDK1, DNA-dependent protein kinase (DNK-
PK), p38 MAP kinase, protein kinase C (PKCα and PKCβ), NIMA-related kinase-6 
(NEK6), mammalian target of rapamycin (mTOR) or the ataxia telangiectasia mutated 
gene product (ATM) as the possible PDK2 (Dong and Liu 2005). 
When AKT is fully active it can phosphorylate a number of important downstream 
targets involved in the regulation of cell survival, cell cycle progression and cellular 
growth. The consensus sequence for AKT phosphorylation is R-X-R-X-X-S/T, where R is 
an arginine residue, S is serine, T is threonine and X is any amino acid.  This motif is a 
common feature of known substrates of AKT and its presence indicates whether a given 
protein may be phosphorylated by AKT (Brazil and Hemmings 2001; Franke 2008). 
AKT can regulate apoptotic machinery by phosphorylating and inactivating pro-
apoptotic factors such as BAD and procaspase-9 and inhibiting the expression of others 
pro-apoptotic factors such Fas-L, IGFBP-1 and Bim by phosphorylation of the forkhead 
family of transcription factors (Osaki, Oshimura et al. 2004; Vara, Casado et al. 2004) 
In addition AKT phosphorylate and activate Ikappa B kinase α (IKKα) which 
phosphorylates IKK, targeting it for degradation. This leads to the nuclear translocation 
and activation of nuclear factor kappaB (NF-kB) and transcription of NF-kB-dependent 
prosurvival genes, including Bcl-XL, caspase inhibitors and c-Myb (Osaki, Oshimura et al. 
2004). The cyclic AMP-response element-binding protein (CREB) is also phosphorylated 
and activated resulting in expression of genes with anti-apoptotic activity like Bcl-2, Mcl-1 
and AKT itself (Osaki, Oshimura et al. 2004; Vara, Casado et al. 2004).  
AKT also promotes the destabilization of p53 by phosphorylating the murine 
double minute-2 protein (Mdm2) and inducing its translocation to the nucleus. The 
complex Mdm2-p53 will leave the nucleus and enters the cytoplasm where p53 is degraded 
through ubiquitination (Osaki, Oshimura et al. 2004).  
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Glicogen synthase kinase-3 (GSK3), mTOR, cyclin-dependent kinase inhibitors 
p21
CIP/WAF1
 and p27
KIP1
, tuberous sclerosis complex 2 (TSC2), GLUT4 are some AKT 
substrates that regulate the cell proliferation (Vara, Casado et al. 2004). 
The inhibition of GSK3 by AKT prevents the phosphorylation of the β-catenin 
which impedes its degradation and consequently permits it translocation to the nucleus 
where it combines with transcription factors. This combination induces the expression of 
several genes, like cyclin D1, which induces cell cycle progression by regulating pRb 
hyperphosphorylation and inactivation (Vara, Casado et al. 2004; Franke 2008). AKT also 
inhibits cyclin-dependent kinase inhibitors p21
CIP/WAF1
 and p27
KIP1
 by retaining them in the 
cytoplasm via phosphorylation. This inhibition leads to the activation of Cyclin/Cdk 
complexes, especially CyclinD1/Cdk4 (Osaki, Oshimura et al. 2004). 
GLUT4, an important glucose transporter, is also regulated by AKT which 
promotes the translocation of GLUT4 to the plasma membrane increasing the uptake of 
glucose (Franke 2008). 
AKT also phosphorylates mTOR which enhances cell growth through dual 
activation of ribosomal S6 kinase (S6K1) and inhibition of the elongation–initiation factor 
E4 binding protein (4E-BP1). Both proteins act as translational regulators (Osaki, 
Oshimura et al. 2004; Smalley and Herlyn 2005). Finally, TSC2 is also phosphorylated by 
AKT. This phosphorylation prevents the inhibition of S6K1 and activation of 4E-BP1 by 
blocking the formation of the TSC1-TSC2 complex (Osaki, Oshimura et al. 2004; Vara, 
Casado et al. 2004). 
 Besides these implications in regulation of cell survival, cell cycle progression and 
cellular growth, AKT was also reported to be involved  in other processes like 
angiogenesis through eNOS activation, invasion and metastasis by inhibiting anoikis and 
stimulating matrix metalloproteinase (MMP) secretion and in the unlimited replicative 
potential by increasing telomerase activity by phosphorylation of hTERT (Hanada, Feng et 
al. 2004; Vara, Casado et al. 2004). 
Since AKT plays an important role in signaling pathways that regulate apoptosis 
and cell growth it is clear that its deregulation could lead to cancer (figure 7).  
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Figure 7: The PI3K-AKT signalling pathway involved in melanoma. 
 
The deregulation of AKT signaling in cancer could be due to alterations of both 
positive and negative regulatory signals. Upstream of AKT, PI3K is activated as a result of 
ligand-dependent activation of receptors. These ligands are frequently overexpressed in 
cancer which may be a way to activate AKT. Another route to AKT activation is 
overexpression or constitutive activation of cell surface receptors (Nicholson and Anderson 
2002; Robertson 2005). 
Other possibility to increased AKT activity is genetic amplifications or mutations 
leading to constitutive activation. Until recently none AKT3 mutation in melanoma was 
reported, nonetheless in 2008 was identified an AKT3 E17K mutation that resulted in AKT 
activation in two melanomas (from one patient) as well as two cell lines (Davies, Stemke-
Hale et al. 2008).  
On the other hand, the overexpression of AKT3 protein is frequently as a result of 
copy number increases of the long arm of chromosome 1 containing the gene. Still, 
The effect of anticancer drugs prodiginines in Protein Phosphatase 1 in melanoma  
Mestrado Biomedicina Molecular  29 
 
expression does not necessarily imply activity, so others mechanisms must contribute to 
AKT activation (Stahl, Sharma et al. 2004; Madhunapantula and Robertson 2009). 
 Loss or decreased of proteins that act as negative regulators of AKT offers another 
mechanism of regulating activity of AKT isoforms. The phosphatases that directly 
dephosphorylate AKT and regulate its activity, like PP1 and PP2A, are possible 
candidates, since treating cells with inhibitors of protein serine/threonine phosphatases 
leads to AKT activation (Andjelković, Jakubowicz et al. 1996). However this interaction 
needs further studies in melanoma. 
 PTEN is another phosphatase that regulates AKT through the conversion of PIP3 in 
PIP2, which causes decreased AKT phosphorylation and activity. Moreover PTEN is 
frequently absent in many cancer types and its absence is related with an increased AKT 
activation (Guldberg, thor Straten et al. 1997). Research on the role of PTEN in melanoma 
suggested that PTEN might be involved in up to 60% of non-familial melanomas 
(Robertson 2005). In recent studies, wild type PTEN protein appears specifically to 
regulate AKT3 activity in melanoma (Stahl, Sharma et al. 2004). This observation agrees 
with the fact that studies of melanoma tumor material from patients have documented 
decreased PTEN expression, mediated through loss of a single copy of chromosome 10 
(Parmiter, Balaban et al. 1988; Robertson 2005). In early melanocytic lesions, loss of 
PTEN, or PTEN haploinsufficiency, occurs by loss of an entire copy of chromosome 10. 
This loss would reduce PTEN expression causing increased AKT3 activation in an early 
phase, in addition to an overexpression of AKT3 in a more advance phase (Robertson 
2005) (figure 8). 
Others studies emphasize the role of cross-talks between AKT3 and MAPK 
pathways in melanoma. It is known that stimulation of B-Raf activity by epidermal growth 
factor can be inhibited by coexpression of AKT. AKT phosphorylates B-RAF at Ser364 
and Ser428 down regulating its catalytic activity. This has been validated in melanoma 
through ectopic expression of active AKT3 in early melanoma cells, which promoted 
anchorage-independent growth by inhibiting V600E B-RAF to lower MAPK pathway 
activity to levels eliminating senescence and promoting tumor progression. The inhibition 
of both proteins was found to synergistically inhibit tumor development due to inhibition 
of AKT3 signalling in PI3K pathways and increased MAPK activity promoting 
senescence. In a spontaneous mouse melanoma model loss of PTEN has been shown to be 
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required for progression of V600E B-RAF nevi into melanomas accentuated the 
importance of AKT3 regulation in this pathway. 
 
 
Figure 8: Schematic representation of melanoma tumour progression showing the timing of the events that promotes 
AKT3 activation. In dysplastic nevus B-RAF mutations appears frequently, however it is not sufficient to induce 
tumorogenesis. Nevertheless the increase of AKT3 activity by decreased of PTEN activity during the radial growth-phase 
and the overexpression of AKT3 during the vertical growth-phase as well as loss or decreased of proteins that act as 
negative regulators are critical for melanoma progression and survival.  
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1.2.3 Prodiginines: new putative therapeutical alternatives to melanoma 
Prodiginines are a family of natural red pigmented tripyrrolic secondary metabolites 
that shows numerous biological activities like antibacterial, antifungal, antiprotozoal, 
antimalarial, immunosuppressive and anticancer properties (Williamson, Fineran et al. 
2007; Perez-Tomas and Vinas 2010). These compounds can be produced by certain Gram-
positive and Gram-negative bacteria isolated from marine and terrestrial environments, 
including actinomycetes, Serratia sp., Hahella sp. Vibrio sp. and Pseudoalteromonas 
(Williamson, Fineran et al. 2007). 
The naturally occurring prodiginines can be divided into those with linear side-
chains like prodigiosin (PG) (figure 9) and undecylprodigiosin and cyclised derivatives, for 
instance, cycloprodigiosin or butylcycloheptylprodiginine.  
The biosynthesis of prodigiosin and derivatives has been extensively studied in 
Serratia marcescens, a Gram-negative bacterium which belongs to the enterobacteriaceae 
family. Prodigiosin is produced by a bifurcated process in which mono and bipyrrole 
precursors are synthesized separately and then assemble to form prodigiosin (Khanafari, 
Assadi et al. 2006; Williamson, Fineran et al. 2007). 
Prodigiosin has the ability to trigger apoptosis. It was proven that prodigiosin 
induces apoptosis rapidly in haematopoietic cancer lines (Montaner, Navarro et al. 2000) 
as well as in cells derived from other human cancers like gastric (Díaz-Ruiz, Montaner et 
al. 2001), colon (Montaner and Pérez-Tomás 2001) or breast (Soto-Cerrato, Llagostera et 
al. 2004). It also induces apoptosis of B and T cells in B-cell chronic lymphocytic 
leukaemia samples (Campas, Dalmau et al. 2003). 
Identify and characterize the targets of prodigiosin is necessary to understand the 
mechanisms of action. So far, four mechanisms of action were suggested by being pH 
modulator, cell cycle inhibitor, DNA cleavage agent and mitogen-activated protein kinase 
(MAPK) regulator (Pérez-Tomás, Montaner et al. 2003). It has further been demonstrated 
that prodigiosin inhibits the PI3K/AKT/GSK3β pathway inducing the dephosphorylation 
of AKT (Soto-Cerrato, Viñals et al. 2007). However, the mechanism underlying this 
dephosphorylation is unknown. 
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Figure 9: Structure of 2-methyl-3-pentyl-6-methoxyprodigiosene (PG). The cytotoxic potency of PG may be attributed to 
the presence of the PG C-6 methoxy substituent (adapted from Williamson, Fineran et al. 2007) 
 
Another molecule, related to prodigiosin that has emerged as a promising candidate 
to act as an anticancer drug, is Obatoclax (GX15-070) (figure 10). Obatoclax (OBX) is a 
hydrophobic cycloprodigiosin derivative developed by GeminX Pharmaceuticals (Daïri, 
Yao et al. 2007). This molecule was reported as a BH3 mimetic, in other words, OBX has 
the ability to bind and antagonize with the anti-apoptotic BCL-2 family members (BCL-2, 
BCL-W, BCL-XL and MCL-1) (Perez-Tomas and Vinas 2010). The inhibition of these 
proteins alters the balance between the pro- and anti-apoptotic proteins inducing apoptosis. 
It was also proven that OBX can lead to the phosphorylation of the pro-apoptotic BH3-
only protein, BIM, and its translocation to the mithocondria, inducing the intrinsic 
apoptotic pathway activation (Perez-Galan, Roue et al. 2008). However it is likely that 
OBX has others mechanisms of action because in acute myeloid leukemia cell lines it can 
induce S-G2 cell cycle arrest in small doses, that are not capable to induce apoptosis or 
decrease viability (Konopleva, Watt et al. 2008). Recently, some studies reported OBX as 
an inducer of autophagy (Jingxuan, Chao et al. 2010; McCoy, Hurwitz et al. 2010). 
However the mechanism by which this happen is not well understood. Some research 
indicate beclin-1 involved in this mechanism given its essential role in the initiation of 
autophagy and its interaction with Bcl-2 through the BH3 domain within beclin-1, 
inhibiting beclin-1 dependent autophagy (Maiuri, Le Toumelin et al. 2007). BH3 mimetics, 
like OBX, are able to disrupt the interaction between Bcl-2 and beclin-1 leading to 
autophagy. 
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Figure 10: Structure of GX15-070 (obatoclax) (adapted from Daïri, Yao et al. 2007) 
 
Despite attempts to treat melanoma using a wide variety of therapies, including 
immune-, radio-, and chemotherapy, survival from disseminated disease remains very 
poor, with a median survival rate of 6 months (Smalley and Herlyn 2005). Understanding 
the pathways that are involved in melanoma proliferation, progression and survival is 
fundamental to develop new therapeutic approaches. One of these important pathways is 
PI3K/AKT due to its role in cell survival, progression and resistance to chemotherapeutic 
agents and because its hyperactivation is relatively frequent in this type of cancer (Luo, 
Manning et al. 2003). Blocking this pathway could simultaneously inhibit the proliferation 
of tumor cells and sensitize them towards apoptosis. Thus, using drugs to inhibit the 
positive regulators or activate the negative regulators of this pathway is a promising 
melanoma therapy. 
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1.3 Aims of Thesis 
 
Bacterial prodiginines and synthetic derivatives (such as prodigiosin and obatoclax, 
respectively) are effective proapoptotic agents with multiple cellular targets, and they are 
active against numerous cancer cell lines, including multi-drug resistant cells, with little or 
no toxicity towards normal cell lines. 
One of the major signalling pathways that is compromised in melanoma is the 
PI3K/AKT pathway. Indeed, it seems that prodigiosin induces the dephosphorylation of 
some protein kinases, such as AKT, being potentially useful in the treatment to this type of 
cancer. However, the mechanism through which prodigiosin induces AKT 
dephosphorylation and thus decreases cell proliferation, is not yet elucidated. Interestingly, 
recently it was shown that PP1 is a major phosphatase involved in the dephosphorylation 
of AKT, modulating its activity.  
The aim of this study is to address if PP1 mediates prodigiosin dependent AKT 
dephosphorylation in melanoma derived cell lines. Therefore we propose to: 
a) Optimize the growth conditions of melanoma cell lines (SK-MEL 5). 
b) Determine the expression levels of PP1 isoforms and AKT/AKTp ratio in the 
presence of prodigiosin and cantharidin (a PP1 inhibitor) in SK-MEL 5 cells by 
western blot. 
c) Characterize the PP1/prodiginines complex using the BIACORE technology. 
d) Propose a model that explains how prodigiosin induces AKT dephosphorilation in 
melanoma derived cell lines and discuss its relevance to melanoma therapy. 
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2 Materials and Methods 
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All solutions compositions are described in appendix 
 
Antibodies 
The primary antibodies used in this study aimed at detecting PP1α, PP1γ, AKT, 
AKTp, MAPK, MAPKp and tubulin. The secondary antibodies used were anti-rabbit and 
anti-mouse. More information is given in table 2 (appendix).  
 
Cell Culture 
Human melanoma cells (SK-MEL-5) were cultured in Minimum Essential Medium 
(MEM) with GlutaMAX 41090 (Gibco) supplemented with 10% (v/v) foetal bovine serum 
(FBS), 1% (v/v) penicillin/streptomycin, 1% (v/v) L-glutamine 200mM, 1% (v/v) non 
essential amino acids (NEAA) at 37ºC and 5% CO2. 
 
Drugs 
Cantharidin (CANT) is available in the Signal Translational Laboratory. 
Prodigiosin and Obatoclax were kindly provided by Dr. Ricardo Pérez from the 
Cancer Cell Biology Research Group of Department of Cell Biology and Pathology at the 
University of Barcelona, Spain.  
 
Sample preparation 
The cell medium was removed and cells collected by adding boiling 1% SDS by 
gently scrapping. The lysates were collected to microtubes. The samples were boiled for 10 
minutes and sonicated for 20 seconds. 
 
BCA protein assay 
The protein content of the samples was determined using BCA protein assay 
(PIERCE). This assay is a detergent-compatible formulation based on bicinchoninic acid 
(BCA) for colorimetric detection and quantification of total protein. The method combines 
the reduction of Cu
2+
 to Cu
+
 by protein in an alkaline medium (the biuret reaction) with 
high sensitivity and selective colorimetric detection of the cuprous cation (Cu
+
) using a 
unique reagent containing bicinchoninic acid. The purple-coloured reaction product of this 
assay is formed by chelation of two molecules of BCA with one cuprous ion. This water 
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soluble complex exhibits a strong absorvance at 562 nm that is linear with increasing 
protein concentration over a broad working range of 20µg/ml to 2000µg/ml. The standarts 
were prepared as described in table 3 (appendix). 
Reactions were initiated by adding 1 ml of WR to 50 µL of each sample. The 
standards and samples were incubated at 37ºC for 30 minutes. The absorbances were then 
measured at 562 nm and a standard curve was prepared by plotting the value for each BSA 
standard against its concentration. Using this curve the protein concentration of each 
sample was determined. 
 
SDS-PAGE 
Samples were subjected to SDS polyacrylamide gel electrophoresis (SDS-PAGE). 
In SDS-PAGE the migration of the proteins is determined by their molecular weight. 
Sodium dodecylsulfate (SDS) is an anionic detergent that denatures proteins by wrapping 
around the polypeptide backbone, conferring a negative charge to the polypeptide in 
proportion to its length. Samples were prepared and 4x loading buffer added. Proteins were 
then resolved on a 10% SDS-PAGE. Gels were run at 100V for approximately 2 hours.  
 
Immunoblotting 
After electrophoresis, proteins were transferred onto a solid support, while keeping 
their positions and then visualized with specific antibodies. Proteins were transferred to 
nitrocellulose membranes overnight at 200mA. 
Immunoblotting of the transferred proteins was performed by initially blocking any 
possible non-specific binding of the primary antibody by immersing the membrane in 5% 
non-fat milk in TBST (blocking solution) for 1h with shaking. Then, membranes were 
incubated with primary antibody (diluted in blocking solution) and left for 2 hours to 
overnight depending on the antibody being used. 
After removing the primary antibody, the membranes were washed three times, 10 
min each, in 1X TBST and the primary antibody was detected with a solution of the 
appropriate secondary antibody, diluted in 3% non-fat milk, in TBST for 1h with shaking. 
Membranes were washed three times, for 10 min and the secondary antibody detected 
using one of the enhanced chemiluminescence detection systems (ECL and ECL Plus kits; 
Amersham Pharmacia Biotech) Excess solution was drained by touching the edge of the 
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membranes against tissue paper and the membrane was gently wrapped with cling-film, 
eliminating all air bubbles. In the dark room, the membrane was placed in a film cassette 
and an autoradiography film was placed on the top. The cassette was closed and the blot 
exposed over a certain period of time. The film was then removed and developed in a 
developing solution, washed in water and fixed in fixation solution.        
 
Quantification and statistical analysis 
 Immunoblots were scanned and quantified using the Quantity One densitometry 
software (Bio-Rad). Data are expressed as means ± SEM of triplicate determinations, from 
at least three independent experiments.  
 
BiaCore – Surface Plasmon Resonance 
To evaluate the interaction between PP1 and prodiginines the Biacore’s Surface 
Plasmon Resonance (SPR) technology was used.This technology is based in three 
cornerstone technologies, the sensor chip technology, the microfluidic system and the 
surface plasmon resonance detection system. The sensor chip consists of a glass coated 
with a thin layer of gold, usually modified with a carboxymethylated dextran layer, which 
forms a hydrophilic environment for the attached molecules, preserving them in a non-
denaturated state. The microfluidic system allows the analyte to pass over the sensor 
surface in a continuous, pulse-free and controlled flow that maintains constant analyte 
concentrations at the sensor chip surface. SPR is a phenomenon that occurs in thin 
conducting films (gold layer) at an interface between a solid support phase (the glass of the 
sensor surface) and a liquid phase (buffer/sample), two media of different refractive index.  
Under conditions of total internal reflection, the light leaks an electromagnetic 
component called evanescent wave field across the gold interface into the sample/buffer 
solution. At a certain combination of angle of incidence and energy (wavelength), the 
incident light excites plasmons in the gold film with a concomitant drop in the intensity of 
the reflected light at this angle (SPR angle). This angle varies as a function of the refractive 
index of the medium near the sensor surface, which change when mass variations occur. In 
others words when the analyte binds to the ligand bound to the sensor chip, the mass 
increases and when it dissociates the mass falls, producing changes in the refractive index 
close to the surface, which are detected as changes in the SPR signals. 
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A sensogram represents changes in SPR angle in real time, with responses 
measured in resonance units (RU) given quantitative information in real time on specificity 
of binding, active concentration of molecule in a sample, kinetics and affinity. One RU 
corresponds to 0,0001º shift in SPR angle (figure 11). 
  
 
Figure 11: Representation of a sensogram. The baseline represents a continuous flow of buffer. An increase in signal 
(complex formation) is observed when the analyte binds to the ligand immobilized on the surface of the sensor chip.  
Then, the sample is replaced by a continuous flow of the buffer and the decrease in signal reflects the dissociation of the 
analyte from the complex formation. A regeneration solution is injected to dissociate the remaining analyte (regeneration) 
and a continuous flow of buffer is used again to wash the sensor chip allowing new analysis with others analytes. The 
monitored response units are directly related to the analyte bound to the surface layer. An operating program allows 
further evaluation of the data analysis. 
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3 Results 
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3.1 Time dependent effect of Cantharidin and Prodigiosin on Akt  
 
In order to evaluate how PG and CANT affect the levels of phosphorylated AKT at 
serine 473, human melanoma SK-MEL-5 cultured cells, were treated with one or other 
compound. A time dose response curve was performed for both. SK-MEL-5 cells were 
grown as previously described and treated with 1 µM (corresponding to the IC50) and 10 
µM CANT [a concentration that inhibits PP1 (Honkanen 1993)] for 30 and 60 minutes 
(min) and the levels of phospho-AKT(S473) were evaluated (figure 12).  
 
 
Figure 12: A - Immunoblot analysis of AKTp (S473) and AKT levels in the presence of cantharidin and prodigiosin. B- 
Quantification of the levels of AKTp/AKT ratio from several experiments. Data are presented as mean ± SEM of at least 
two independent experiments. 
 
In SK-MEL-5 cells, treatment with PG decreased the ratio AKTp/AKT total in 50% 
at 30 min and in 75% at 60 min, as shown in figure 12. By contrast, CANT treatment 
increased the ratio AKTp/AKT twofold at 30 minutes and four fold at 60 min. In this 
experiment two controls were used CT and CT (DMSO), collected at 60 min. CT was the 
control without any treatment; however in CT (DMSO) the cells were treated with DMSO 
since the drugs, prodigiosin and cantharidin, were diluted in DMSO. Tubulin was used as 
loading control.  
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3.2 PP1 binds prodiginines 
 
In order to address if PP1 is a target to prodiginines, a real-time interaction analysis 
using Surface Plasmon Resonance (SPR) technology was used. Protein Phosphatase 1 
(PP1) (New England BioLabs # P0754; Rabbit recombinant protein amino acid 1-330 from 
alpha isoform; MW: 37.5KDa; pI: 5.94) was covalently attached to a CM5 sensor chip 
according to amine coupling protocol. Activation of the surface with 1-ethyl-3 (3-
dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS) was 
followed by injection of PP1. The excess of reactive groups were deactivated with 
ethanolamine.  PP1 was diluted to 1ng/ µL in acetate buffer pH 4.8, and immobilized to a 
level of 3982 response units (RU) into flow-cell 3. Flow cell 1 was activated and assigned 
as “blank” control. All the assays were carried out at 25ºC using HBSN as buffer running 
supplemented with 100 mM MgCl2. The same buffer was used to dilute the prodiginines. 
The run started with three start-up cycles, where buffer was first injected followed by 
prodiginines injection cycles. Zero concentration samples were used as blanks. The 
prodiginines were injected over sensor surfaces for 60s at 30 µl/min. The complexes were 
regenerated back using 25 mM NaOH.  
First, the ability of PG to interact with PP1 was assayed. Nevertheless, technical 
problems (PG precipitation in the buffer used in Biacore as well as aggregation problems 
during the experiments) did not allowed to make any reliable conclusions. Thus we tested 
the interaction of PP1 with another member of the prodiginine family, OBX. Predicted 
kinetic and affinity constants (graphic 1 and 2 and table 1) confirmed the specificity and 
high affinity of the binding with the following concentrations: 0.04nM, 0.078nM, 
0.625nM, 1.25nM, 2.5nM (figure 13 A and B). 
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Figure 13A. Kinetic characterization of PP1α-OBX binding. Sensorgrams (in color) and curve fits (black lines) 
(assuming 1:1 interactions) are shown. 
 
 
Figure 13B. Affinity characterization of PP1α-OBX binding. 
 
Table 1: Values of kinetics and affinity constants after data analysis by BiaCore Evaluation Software. The similarity 
between both KD values (in kinetics and affinity) demonstrates the specificity of the binding.  
 
 
OBX bound to the tested isoform of PP1, PP1α, with a calculated KD in a range of 
nanomolar (1.8E
-10
 ± 1.1E
-10
 M) (Table 1). The KD obtained indicates a high affinity 
interaction. Moreover, the disassociation constant Kd (0.017 s
-1
) means that 1.7 percent of 
the complexes decays per second demonstrating that OBX/PP1 complex is stable and the 
association constant, Ka, which describes the rate of complex formation, is 1.626E
8
, 
indicating the number of complexes formed per second in one molar solution of OBX and 
Ligand Analyte 
Kinetics Affinity 
Ka 
(1/Ms) 
Kd (1/s) KD (M) 
Rmax 
(RU) 
Chi2 
(RU2) 
KD(M) 
Rmax 
(RU) 
Chi2 
(RU2) 
PP1α OBX 1.626E8 0.01703 1.047E-10 3.0 0.121 2.599E-10 2.1 0.151 
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PP1. The Chi
2 
value is 0.121 in kinetics and 0.151 in affinity. Since Chi
2
 is a statistical 
measure of how closely the model fits the experimental data and should have values lower 
than about 10 for a good fit to sensorgrams with normal noise levels, those values show the 
trustworthy of these experiments. Lastly, the RU units were lower than expect (3.0 in 
kinetics and 2.1 in affinity) being the expected a value nearly 15.0 however this could be 
because when PP1 was immobilized, it was attached to the sensor surface in a 
conformation that not allowed a completely interaction with prodiginines. Nonetheless, 
these results confirm the interaction of PP1 and OBX forming a stable and specific 
complex.   
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3.3 Prodigiosin action on PP1 isoform specificity 
 
To address the specific synergic effect of PG and CANT on PP1 isoforms, 
treatment with PG was performed preceded by CANT pre-incubation on SK-MEL-5 
cultured cells. SK-MEL-5 cells were pre-incubated for 30 min with 10 µM CANT follow 
by joint incubation with 0.15 µM (figures 14 and 16) and 0.38 µM (figures 15 and 17) PG 
(corresponding to the IC12,5 and IC25, respectively) for 30 minutes and 60 minutes. PG 
IC12,5 and IC25 were used since at these concentrations an effect on AKT 
dephosphorylation is already seen (unpublished data from our Spanish collaborators) In the 
CT (CANT) cells were incubated for 90 min with CANT. Tubulin was used as loading 
control.  
 
 
Figure 14: A- Effect of PG IC12,5 treatment after CANT action on PP1α levels. B- Quantification of PP1α from several 
experiments. Data are presented as mean ± SEM of at least two independent experiments. 
 
As figure 14 shows CANT treatment followed by PG IC12,5 treatment during 30 
min did not change the levels of PP1α. However with PG IC12,5 treatment during 60 min 
PP1α levels increased 15%.  
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Figure 15: A- Effect of PG IC25 treatment after CANT action on PP1α levels. B- Quantification of PP1α from several 
experiments. Data are presented as mean ± SEM of at least two independent experiments. 
 
Using a higher concentration of PG (IC25) (figure15) a similar pattern was 
demonstrated with that obtained with PG IC12,5. CANT treatment followed by PG IC25 
treatment during 30 min did not alter PP1α levels, yet, as happened in the previous 
experiment, the PG treatment for 60 min increased PP1α amounts, in this situation more 
than 50% compared with control. These results suggest that PG needs one hour to have 
some effect on PP1α with a CANT pre-incubation, and a higher concentration of PG have 
more impact in PP1α levels. 
 The pattern of other PP1 isoform, PP1γ, was also explored (figures 16 and 17). 
 
 
Figure 16: A- Effect of PG IC12,5 treatment after CANT action on PP1γ levels. B- Quantification of PP1γ from several 
experiments. Data are presented as mean ± SEM of at least two independent experiments. 
 
 The pattern presented by PP1γ was unexpectedly different from PP1α. At 30 min of 
PG IC12,5 treatment after CANT pre-incubation for 30 min, the levels of PP1γ increased 
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80% compared with control levels and at 60 min with PG IC12,5 treatment the PP1γ 
amounts decreased nearly 90% compared with levels achieved at 30 min with PG IC12,5.  
As in PP1α experiments these experiments were repeated with PG at higher 
concentrations (IC25). 
 
 
Figure 17: A- Effect of PG IC25 treatment after CANT action on PP1γ levels. B- Quantification of PP1γ from several 
experiments. Data are presented as mean ± SEM of at least two independent experiments. 
 
The results using PG IC25 treatment showed the same pattern as PG IC12,5 treatment. 
CANT treatment followed by PG IC25 treatment during 30 min increased the PP1γ levels 
by 20% while PG IC25 treatment during 60 min decreased PP1γ levels 60% compared 
with control levels. These data clearly demonstrate that PG have a different effect in the 
levels of the two PP1 isoforms. 
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3.4 PP1α and PP1γ act on different signaling pathways    
 
The different responses of the two isoforms of PP1, PP1α and PP1γ, to PG treatment 
after CANT treatment, in human melanoma cancer cells, may have an exclusive 
downstream effect on particular genes of relevant signaling cascades. Knowing that AKT 
phosphorylation is affected by PG we evaluated the changes associated with PG on AKT 
and MAPK pathways, two interconnected pathways, and looked if they were being 
affected in the same way as PP1 isoforms were (figure 18 and 19).  
 
 
Figure 18: A- Effect of PG IC12,5 treatment after CANT action on AKTp/AKT ratio levels. B- Quantification of 
AKTp/AKT ratio from several experiments. Data are presented as mean ± SEM of at least two independent experiments. 
 
As the results show the ratio AKTp/AKT increased approximately 80% with the PG 
IC12,5 treatment for 30 min after CANT pre-incubation. Nonetheless, the ratio 
AKTp/AKT decreased 60% with PG treatment during 60 min. 
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Figure 19: A- Effect of PG IC25 treatment after CANT action on AKTp/AKT ratio levels. B- Quantification of 
AKTp/AKT ratio from several experiments. Data are presented as mean ± SEM of at least two independent experiments. 
 
 The same AKTp/AKT pattern was established with PG IC25 treatment. At 30 min 
with PG IC25 treatment the AKTp/AKT ratio, as in the previous treatment, increased 80% 
but when treated for 60 min the ratio decreased by 65%, suggesting that, as showed in 
PP1α experiments, PG needs one hour to have some effect. These hypothesis corroborate 
with the fact that PP1α levels did not change with PG treatment for 30 min because CANT 
was inhibiting PP1α which consequently will induce an increased in AKTp/AKT ratio. On 
the other hand, with PG treatment for 60 min, PG seems to start to have some effect in 
PP1α levels inciting the decreased of AKTp/AKT ratio. 
 The levels of MAPKp/MAPK ratio were also evaluated (figure 20 and 21). 
 
 
Figure 20: A- Effect of PG IC12,5 treatment after CANT action on MAPKp/MAPK ratio levels. B- Quantification of 
MAPKp/MAPK ratio from one experiment. 
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Concerning the MAPKp/MAPK ratio, our preliminary experiments demonstrated 
an inverse behavior in comparison to AKTp/AKT ratio. At 30 min MAPKp/MAPK levels 
decreased in 45% with CANT treatment for 30 min followed by PG IC12,5 treatment for 
30 min. However with the same treatment but with 60 min of PG IC12,5, MAPKp/MAPK 
ratio increased 55% compared with the previous treatment.  
 
 
 
Figure 21: A- Effect of PG IC25 treatment after CANT action on MAPKp/MAPK ratio levels. B- Quantification of 
MAPKp/MAPK ratio from one experiment. 
 
In the same way, the treatment with PG IC25 for 30 min followed by a treatment 
with CANT for 30 min decreased MAPKp/MAPK ratio in 90% while the treatment with 
PG IC25 for 60 min followed by a treatment with CANT for 30 min increased 70% 
compared with the previous treatment.  
In conclusion, the ratios AKTp/AKT and MAPKp/MAPK evaluated in SK-MEL-5 
cells, after CANT treatment and PG treatment clearly show that they are changing in a 
pattern related to PP1α and PP1γ, respectively, suggesting that the first is acting on the 
dephosphorylation of AKT and the second on MAPK. 
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4 Discussion 
 
The effect of anticancer drugs prodiginines in Protein Phosphatase 1 in melanoma  
Mestrado Biomedicina Molecular  54 
 
Protein phosphorylation is a major mechanism to regulate cellular function. When 
the balance between kinases and phosphatases is lost, pathological states are installed. 
Cancer is not an exception. There are many examples where the altered phosphorylation of 
key proteins has been described. PP1, a major Serine/Threonine-Phosphatase, whose 
activity is dependent on the partners it binds to, is being intensively studied as a target for 
pharmacological intervention due to its high potentialities (Fardilha, Esteves et al. 2010). 
Prodigiosin (PG), a molecule with anticancer properties, induces the 
dephosphorylation of AKT (Soto-Cerrato, Viñals et al. 2007). We used human melanoma 
cultured cells where the AKT pathway has been shown to be hyperactivated (Stahl, Sharma 
et al. 2004). 
We evaluated the levels of phospho-AKT (S473) after CANT treatment, a PP1 
inhibitor, which resulted in an increase in AKT phosphorylation at 30 and 60 min. 
Therefore, AKT is at least in part dephosphorylated by PP1. At the same time, the levels of 
phospho-AKT (S473) decreased with PG treatment, as expected. Nevertheless the 
mechanism by which PG leads to the dephosphorylation of AKT is not known. In an 
attempt to understand how PG induced AKT dephosphorylation we hypothesized that PG 
is acting through PP1. Thus we performed binding assays using Biacore technology and 
showed that prodiginines bind to PP1 in a specific manner. In fact, a similar assay was 
performed to test the binding of PP1 (same isoform) with two PP1 inhibitors (CANT and 
okadaic acid) (Stenlund, Frostell-Karlsson et al. 2006). Although the immobilization 
conditions and buffers were different, comparing the results, we can draw some interesting 
conclusions. The KD for PP1α/OBX binding is the highest (OBX has the highest affinity) 
thus OBX can display CANT from PP1. Nevertheless, PP1α/CANT is the most stable 
complex since its Kd is the lowest (Stenlund, Frostell-Karlsson et al. 2006). 
After demonstrating that PP1 inhibition increases phosphorylation of AKT and that 
OBX, a prodiginine family member, binds to PP1 we evaluate the combined conditions of 
PP1 inhibition and PG treatment, in human melanoma cultured cells, on AKT 
phosphorylation. The CANT pre-treatment for 30 minutes, as suggested by preliminary 
results and by others (Honkanen 1993) should inhibit PP1. However the results are very 
clear and show an increase in the levels of PP1 that must be due to PG. Interestingly, the 
alterations induced on the different PP1 isoforms are dissimilar. Thus, probably PG is 
acting differently on PP1α and PP1γ. There is no literature concerning PP1 isoform 
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specific inhibition or enhancement by small molecules opening very interesting issues 
concerning the above data. PG could displace CANT from PP1 and somehow alter the 
amount of PP1 in the cell. The duration of treatment is too short to induce changes in 
protein expression at the gene level. Nonetheless, one can explain the decrease of PP1γ 
amounts with time (figures 16 and 17) by an increase in protein degradation, induced by a 
high affinity binding of PG to PP1γ (this effect should be further confirmed) that may 
target it to degradation. The PP1γ peak at 30 minutes (PG IC12,5), corresponding to an 
increase of 80% (figure 16), may correlate to a compensatory effect resulting, for instance, 
from PP1γ mRNA local translation (Warner, Bearss et al. 2003), which could be bypassed 
through increasing PG concentration or time of incubation. Concerning PP1α, we 
hypothesized that PG could have lower affinity to it and its levels could compensate for the 
PP1γ decreased, increasing in 60% comparing to the control at 60 minutes (PG IC25) 
(figure 15), but also by PP1α possible mRNA local translation (Warner, Bearss et al. 
2003). 
The pattern of PP1α levels correlate with the dephosphorylated AKT. The same is 
not true for PP1γ, suggesting that prodigiosin action could be by PP1α action on AKT. 
Trying to identify PP1 function  we went to check MAPK expression, a kinase that belongs 
to a signaling cascade that cross-talks with the AKT cascade and that is inhibited when the 
AKT signaling pathway is active (Inamdar, Madhunapantula et al. 2010). Also, both 
MAPK and AKT signaling cascades have been reported to be altered in melanoma 
(Inamdar, Madhunapantula et al. 2010). Surprisingly, the phosphorylation of MAPK was 
increased when PP1γ was decreased. Although, MAPK is describe as a PIP (Quevedo, 
Salinas et al. 2003), a regulation of MAPK activity by PP1 was not found, so these 
variances are not a direct consequence of PP1γ. Nonetheless PP1 is able to inactivate 
MEK1/2, an upstream kinase that phosphorylates and activate MAPK indicating that PP1γ 
could be involved in MAPKp alterations (figure 22) (Manfroid, Martial et al. 2001). Still it 
is possible that other regulators are involved in MAPKp/MAPK alteration like AKT. In 
fact, the decrease in MAPKp/MAPK corresponds to an increase in AKTp/AKT which 
suggests that AKT could inhibit MAPK pathway by phosphorylating RAF at Ser259, 
inactivating MAPK pathway (figure 22) (Zimmermann and Moelling 1999).  
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 Figure 22: Schematic representation of MAPK proposed regulation by AKT and PP1 isoforms.
Model for the action of PP1α and PP1γ on AKT and MAPK pathway and how it is affected 
by prodiginines 
The identification of targets to pharmacologically interfering with signaling pathways 
has largely interested the research community and also the pharmaceutical companies for the 
last decade. Recently, Protein Phosphatases have become also prime focus of attention, in 
particular PP1/PIP complexes due to its specificity (McConnell and Wadzinski 2009). In what 
concerns cancer, several components of signaling cascades have been shown to be 
deregulated and, apart from that, more than one cascade may contribute to the pathogenesis of 
a certain type of cancer. For instance, in melanoma several studies have shown the cross-talk 
between the MAPK and the AKT signaling cascades (Inamdar, Madhunapantula et al. 2010), 
B-RAF activity increases after treatment with an AKT inhibitor in melanoma cells (Guan, 
Figueroa et al. 2000; Merighi, Benini et al. 2006). Interaction between different signaling 
pathways can control the action of drugs, turning them more or less effective or promote drug 
resistance. Several studies have shown that the cross-talk between AKT and MAPK pathways 
can be used more efficiently to treat melanoma by inhibiting AKT, promoting apoptosis and 
activating RAF to promote senescence (Inamdar, Madhunapantula et al. 2010).  Here we 
propose that PP1α preferentially binds AKT and PP1γ interacts preferentially with MAPK. 
The phosphorylation states of both AKT and MAPK in a basal situation will depend on many 
factors. PG will bind preferentially to PP1γ taking it to degradation, leading to increasing 
MAPK phosphorylation (figure 23). Ultimately, this will lead to senescence (Inamdar, 
Madhunapantula et al. 2010). At the same time PP1α is bound to AKT, promoting its 
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dephosphorylation and thus cell apoptosis (figure 23) (Inamdar, Madhunapantula et al. 2010; 
Xiao, Gong et al. 2010).  
 
 
Figure 23: Proposed model of PG action in melanoma. A- Cantharidin inhibits PP1 isoforms activity leading to an increase 
of phosphorylated AKT that will restrain MAPK phosphorylation levels. These two pathways promote cell proliferation, 
invasion and survival. B- PG could bind to PP1 isoforms, more specifically to PP1γ and displace CANT. PP1γ will be send to 
degradation, preventing its inhibition on MAPK pathway and PP1α will inhibit AKT signalling that on the one hand will 
induce apoptosis by direct effect of this inhibition and, on the other hand, will promote senescence indirectly by reducing the 
inhibition of MAPK pathway via AKT.    
 
Care must be taken when targeting one kinase for a single signaling cascade. A kinase 
may have different substrates related to several cellular events and for that reason the 
treatment will not be specific. Also, several signaling cascades might be deregulated, thus it 
would be better to target an upstream molecule. This strategy may also be dangerous due to 
non-specificity. Specificity can be increased by targeting PP1 isoform specific complexes 
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(Fardilha, Esteves et al. 2011).  Therefore we propose to target specific PP1/PIP complexes, 
unique to certain signaling pathways and also from specific cell types, using small molecules 
that can disrupt or enhance the complexes.  
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5 Conclusion and Future Work 
 
The effect of anticancer drugs prodiginines in Protein Phosphatase 1 in melanoma  
Mestrado Biomedicina Molecular  60 
 
To completely understand melanoma and to develop an effective therapy against it is 
necessary to identify and target pathways and genes that are underlying its features. 
Prodigiosin, a new anticancer drug, seems to alter two critical molecules, AKT and MAPK 
that are profoundly involved with melanoma lethal characteristics (extraordinary metastatic 
ability and resistance to chemo and radiotherapy). These variations appear to be connected 
with the alteration in phosphorylation state and with the levels of Protein Phosphatase 1, a 
major Serine/Threonine phosphatase that regulates several key proteins, including AKT and 
probably MAPK.         
 
From these results we can conclude the following: 
1. PP1 is an important AKT regulator in melanoma (figure 12) 
2. Prodigiosin dephosphorylates AKT in melanoma (figure 12) 
3. PP1 binds to prodiginines (figure 13) 
4. Prodigiosin has a different effect on PP1 isoforms (figures 14, 15, 16 and 17) 
5. MAPK activity is altered by prodigiosin action (figures 20 and 21)  
Clearly our results need to be confirmed but raised very interesting and important 
questions. They open new avenues for future research in the field of Protein Phosphatases in 
cancer therapy. In fact, it is the first time that a drug is described to have a different effect on 
different PP1 isoforms. 
Future work includes (figue 24): 
1. Repeat Biacore experiments to optimize PP1α binding conditions and to 
improve RU and also show that PP1γ could bind to prodiginines more 
specifically than PP1α.  
2. Silencing PP1 isoforms by RNAi and then treat cells with prodigiosin to prove 
unequivocally that PP1 is the major player in prodigiosin mechanism of action 
and that PP1 isoforms have different roles in this process.  
3. Repeat these experiments in other melanoma cell lines in different progression 
states as well as in other types of cancer cell lines, to see if this action is cell 
specific or is more sensitive or resistant in different melanoma stages and in 
different types of cancer.  
4. Confirm the hypothesis of prodigiosin taking PP1γ to degradation and 
increasing PP1α levels by local translation. 
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Figure 24: Schematic representation of future work proposed to achieve categorical conclusions. 
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Table 2 – Antibodies dilutions 
 
 
Table 3 – BCA Standarts 
 
 
 
 
 
BSA, bovine serum albumin; WR, Working reagent (to prepare WR 50 pars of BCA reagent A was mixed with 1 
part of reagent B) 
 
 
Solutions  
LGB (Lower Gel Buffer) 
To 900 ml of deionized H2O add:  
Tris 181.65 g 
SDS  4 g  
Mix until the solutes have dissolved. Adjust the pH to 8.9 and adjust the volume to 1L with 
deionized H2O. 
 
 
Antibodies Dilutions Company 
Secondary 
antibody 
Dilutions 
PP1α 1:2500 CBC2C Anti-rabbit 1:5000 
PP1γ 1:5000 CBC3C Anti-rabbit 1:5000 
AKT 1:1000 Cell Signaling Anti-rabbit 1:5000 
AKTp (S473) 1:1000 Cell Signaling Anti-rabbit 1:5000 
MAPK 1:1000 BD Biosciences Anti-mouse 1:5000 
MAPKp 
(T202/Y204) 
1:1000 Santa Cruz Anti-rabbit 1:5000 
Tubulin 1:1000 Zymed Anti-mouse 1:5000 
Standards BSA (µL) 1%SDS (µL) Protein mass (µg) WR (ml) 
P0 - 50 0 1 
P1 1 49 2 1 
P2 2 48 4 1 
P3 5 45 10 1 
P4 10 40 20 1 
P5 20 30 40 1 
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UGB (Upper Gel Buffer) 
To 900 ml of deionized H2O add:  
Tris 75.69 g 
Mix until the solute has dissolved. Adjust the pH to 6.8 and adjust the volume to 1L with 
deionized H2O. 
 
30% Acrylamide/0.8% Bisacrylamide 
To 70 ml of deionized H2O add: 
Acrylamide 29.2 g 
Bisacrylamide 0.8 g 
Mix until the solutes have dissolved. Adjust the volume to 100 mL with deionized H2O. Filter 
through a 0.2 μm filter and store at 4 °C. 
 
10% APS (ammonium persulfate) 
In 10 ml of deionized H2O dissolve 1 g of APS.  
 
10% SDS (sodium dodecilsulfate) 
In 10 ml of deionized H2O dissolve 1 g of SDS. 
 
(4x) Loading Gel Buffer  
1 M Tris solution (pH 6.8) 2.5 ml (250 mM) 
SDS    0.8 g (0.8%) 
Glycerol   4 ml (40%) 
β-Mercaptoethanol  2 ml (2%) 
Bromophenol blue  1 mg (0.01 %) 
Adjust the volume to 10 ml with deionized H2O. Store in darkness at RT. 
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1 M Tris (pH 6.8) solution 
To 150 ml of deionized H2O add: 
Tris base 30.3 g 
Adjust the pH to 6.8 and adjust the final volume to 250 ml. 
 
10x Running Buffer  
Tris  30.3 g (250 mM) 
Glycine              144.2 g (2.5 M) 
SDS  10 g (1%) 
Dissolve in deionized H2O, adjust the pH to 8.3 and adjust the volume to 1 L. 
 
10x Transfer buffer  
Tris  3.03 g (25 mM) 
Glycine               14.41 g (192 mM) 
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the volume to 800 ml 
with deionized H2O. Just prior to use add 200 ml of methanol (20%). 
 
10x TBS (Tris buffered saline)  
Tris               12.11 g (10 mM) 
NaCl               87.66 g (150 mM) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionized H2O.  
 
10x TBST (TBS + Tween)  
Tris  12.11 g (10 mM) 
NaCl  87.66 g (150 mM) 
Tween 20 5 ml (0.05%) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionized H2O.  
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